Recursion Pharmaceuticals
Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis.
REC-1245 (RBM39 degrader, phase 1/2), REC-4881 (MEK1/2, phase 2 in FAP with FDA registrational discussions), REC-4539 (LSD1), REC-617 (CDK7), REC-7735 (PI3Kα H1047R), REC-3565 (MALT1), REC-102 (ENPP1). Reported revenue shortfalls alongside pipeline progress in Q1 2026.
Pages like this
not linked directly; found by shared links- InstitutionCancer Center at Illinois
Shares AI-driven drug & target discovery, The valley of death between lab and product, Preclinical models that do not predict people.
- CompanyInsilico Medicine
Shares A virtual cancer cell that predicts what a drug will do before you test it, AI-driven drug & target discovery, The valley of death between lab and product.
- IdeaAutomated combination discovery: patient-sample screens feeding Bayesian platform trials
Shares AI-driven drug & target discovery, Preclinical models that do not predict people, Colorectal cancer.
- IdeaGet biomarker-directed aspirin after colorectal surgery into labels and guidelines
Shares PIK3CA / PI3K-alpha, No incentive to repurpose cheap drugs, Colorectal cancer.
- TrialALASCCA
Shares PIK3CA / PI3K-alpha, No incentive to repurpose cheap drugs, Colorectal cancer.
- IdeaIn silico trials to choose the dose before the first patient
Shares AI-driven drug & target discovery, Preclinical models that do not predict people.
- IdeaAn open-science consortium on the undruggable drivers, open until a candidate
Shares AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation), RAS / RAF / MEK / ERK (MAPK).
- TechnologyHigh-throughput screening and DNA-encoded libraries
Shares AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation).